Introduction: Compounds present in Cannabis sativa such as phytocannabinoids and terpenoids may act in concert to elicit therapeutic effects. Cannabinoids such as Δ 9 -tetrahydrocannabinol (Δ 9 -THC) directly activate cannabinoid receptor 1 (CB 1 ) and cannabinoid receptor 2 (CB 2 ); however, it is not known if terpenoids present in Cannabis also affect cannabinoid receptor signaling. Therefore, we examined six common terpenoids alone, and in combination with cannabinoid receptor agonists, on CB 1 and CB 2 signaling in vitro . Materials and Methods: Potassium channel activity in AtT20 FlpIn cells transfected with human CB 1 or CB 2 receptors was measured in real time using FLIPR ® membrane potential dye in a FlexStation 3 plate reader. Terpenoids were tested individually and in combination for periods up to 30 min. Endogenous somatostatin receptors served as a control for direct effects of drugs on potassium channels. Results: α-Pinene, β-pinene, β-caryophyllene, linalool, limonene, and β-myrcene (up to 30–100 μM) did not change membrane potential in AtT20 cells expressing CB 1 or CB 2 , or affect the response to a maximally effective concentration of the synthetic cannabinoid CP55,940. The presence of individual or a combination of terpenoids did not affect the hyperpolarization produced by Δ 9 -THC (10 μM): (CB 1 : control, 59%±7%; with terpenoids (10 μM each) 55%±4%; CB 2 : Δ 9 -THC 16%±5%, with terpenoids (10 μM each) 17%±4%). To investigate possible effect on desensitization of CB 1 responses, all six terpenoids were added together with Δ 9 -THC and signaling measured continuously over 30 min. Terpenoids did not affect desensitization, after 30 min the control hyperpolarization recovered by 63%±6% in the presence of the terpenoids recovery was 61%±5%. Discussion: None of the six of the most common terpenoids in Cannabis directly activated CB 1 or CB 2 , or modulated the signaling of the phytocannabinoid agonist Δ 9 -THC. These results suggest that if a phytocannabinoid–terpenoid entourage effect exists, it is not at the CB 1 or CB 2 receptor level. It remains possible that terpenoids activate CB 1 and CB 2 signaling pathways that do not involve potassium channels; however, it seems more likely that they may act at different molecular target(s) in the neuronal circuits important for the behavioral effect of Cannabis .
Background and Purpose: The morbidity and mortality associated with recreational use of synthetic cannabinoid receptor agonists (SCRAs) may reflect strong activation of CB1receptors and is a major health concern. The properties of SCRA at CB1receptors are not well defined. Here we have developed an assay to determine acute CB1receptor efficacy using receptor depletion with the irreversible CB1receptor antagonist AM6544, with application of the Black and Leff operational model to calculate efficacy.Experimental Approach: Receptor depletion in mouse AtT‐20 pituitary adenoma cells stably expressing human CB1receptors was achieved by pretreatment of cells with AM6544 (10 μM, 60 min). The CB1receptor‐mediated hyperpolarisation of AtT‐20 cells was measured using fluorescence‐based membrane potential dye. From data fit to the operational model, the efficacy (τ) and affinity (KA) parameters were obtained for each drug.Key Results: AM6544 did not affect the potency or maximal effect of native somatostatin receptor‐induced hyperpolarization. Theτvalue of ∆9‐THC was 80‐fold less than the reference CB receptor agonist CP55940 and 260‐fold less than the highest efficacy SCRA, 5F‐MDMB‐PICA. The operational efficacy of SCRAs ranged from 233 (5F‐MDMB‐PICA) to 28 (AB‐PINACA), with CP55940 in the middle of the efficacy rank order. There was no correlation between theτandKAvalues.Conclusions and Implications: All SCRAs tested showed substantially higher efficacy at CB1receptors than ∆9‐THC, which may contribute to the adverse effects seen with these drugs but not ∆9‐THC.
26 February 2020 in Pharmacology Research & Perspectives
Synthetic cannabinoid receptor agonists (SCRAs) are new psychoactive substances associated with acute intoxication and even death. However, the molecular mechanisms through which SCRAs may exert their toxic effects remain unclear—including the potential differential activation of G protein subtypes by cannabinoid receptor type 1 (CB1), a major target of SCRA. We measured CB1‐mediated activation of Gαs and Gαi/o proteins by SCRAs by examining stimulation (pertussis toxin, PTX treated) as well as inhibition (non‐PTX treated) of forskolin (FSK)‐induced cyclic adenosine monophosphate (cAMP) accumulation in human embryonic kidney (HEK) cells stably expressing CB1. Real‐time measurements of stimulation and inhibition of cAMP levels were made using a BRET biosensor. We found that the maximum concentration of SCRAs tested (10 µmol L−1), increased cAMP levels 12%‐45% above that produced by FSK alone, while the phytocannabinoid THC did not significantly alter cAMP levels in PTX‐treated HEK‐CB1 cells. All SCRAs had greater potency to inhibit FSK‐induced cAMP levels than to stimulate cAMP levels. The rank order of potencies for SCRA stimulation of cAMP (Gαs) was PB‐22 > 5F‐MDMB‐PICA > JWH‐018 ≈ AB‐FUBINACA > XLR‐11. By contrast, the potency of SCRAs for inhibition of cAMP (Gαi/o) was 5F‐MDMB‐PICA > AB‐FUBINACA > PB‐22 > JWH‐018 > XLR‐11. The different rank order of potency and EMax of the SCRAs to stimulate Gαs‐like signaling compared to Gαi/o signaling suggests differences in G protein preference between SCRAs. Understanding the apparent differences among these drugs may contribute to unravelling their complex effects in humans.
Background Synthetic cannabinoids are a commonly used class of recreational drugs that can have significant adverse effects. There have been sporadic reports of co-consumption of illicit drugs with rodenticides such as warfarin and brodifacoum (BFC) over the past 20 years but recently, hundreds of people have been reported to have been poisoned with a mixture of synthetic cannabinoids and BFC. We have sought to establish whether BFC directly affects cannabinoid receptors, or their activation by the synthetic cannabinoid CP55940 or the phytocannabinoid Δ9-tetrahydrocannabinol (Δ9-THC). Methods The effects of BFC on the hyperpolarization of wild type AtT20 cells, or AtT20 cells stably expressing human CB1- or CB2- receptors, were studied using a fluorescent assay of membrane potential. The effect of BFC on CB1- and CB2-mediated inhibition of forskolin-stimulated adenylyl cyclase (AC) activation was measured using a BRET assay of cAMP levels in HEK 293 cells stably expressing human CB1 or CB2. Results BFC did not activate CB1 or CB2 receptors, or affect the hyperpolarization of wild type AtT20 cells produced by somatostatin. BFC (1 µM) did not affect the hyperpolarization of AtT20-CB1 or AtT20-CB2 cells produced by CP55940 or Δ9-THC. BFC (1 µM) did not affect the inhibition of forskolin-stimulated AC activity by CP55940 in HEK 293 cells expressing CB1 or CB2. BFC (1 µM) also failed to affect the desensitization of CB1 and CB2 signaling produced by prolonged (30 min) application of CP55940 or Δ9-THC to AtT20 cells. Discussion BFC is not a cannabinoid receptor agonist, and appeared not to affect cannabinoid receptor activation. Our data suggests there is no pharmacodynamic rationale for mixing BFC with synthetic cannabinoids; however, it does not speak to whether BFC may affect synthetic cannabinoid metabolism or biodistribution. The reasons underlying the mixing of BFC with synthetic cannabinoids are unknown, and it remains to be established whether the “contamination” was deliberate or accidental. However, the consequences for people who ingested the mixture were often serious, and sometimes fatal, but this seems unlikely to be due to BFC action at cannabinoid receptors.
Background: Synthetic cannabinoids are a commonly used class of recreational drugs that can have significant adverse effects. There have been sporadic reports of co-consumption of illicit drugs with rodenticides such as warfarin and brodifacoum (BFC) over the past 20 years but recently, hundreds of people have been reported to have been poisoned with a mixture of synthetic cannabinoids and BFC. We have sought to establish whether BFC directly affects cannabinoid receptors, or their activation by the synthetic cannabinoid CP55940 or the phytocannabinoid Δ 9 -tetrahydrocannabinol (Δ 9 -THC). Methods: The effects of BFC on the hyperpolarization of wild type AtT20 cells, or AtT20 cells stably expressing human CB 1 - and CB 2 -mediated receptors, were studied using a fluorescent assay of membrane potential. The effects of BFC on CB 1 and CB 2 mediated inhibition of forskolin-stimulated adenylyl cyclase (AC) activation was measured using a BRET assay of cAMP levels in HEK 293 cells stably expressing human CB 1 and CB 2 . Results: BFC did not activate CB 1 or CB 2 receptors, or affect the hyperpolarization of wild type AtT20 cells produced by somatostatin. BFC (10 µ M) did not affect the hyperpolarization of AtT20-CB 1 or AtT20-CB 2 cells produced by CP55940 or Δ 9 -THC. BFC (1 µ M) did not affect the inhibition of forskolin-stimulated AC activity by CP55940 in HEK 293 cells expressing CB 1 or CB 2 . BFC (1 µ M) also failed to affect the desensitization of CB 1 and CB 2 signalling produced by prolonged (30 min) application of CP55940 or Δ 9 -THC to AtT20 cells. Discussion: BFC is not a cannabinoid receptor agonist, and appeared not to affect cannabinoid receptor activation. Our data suggests there is no pharmacodynamic rationale for mixing BFC with synthetic cannabinoids, however, it does not speak to whether BFC may affect synthetic cannabinoid metabolism or biodistribution. The reasons underlying the mixing of BFC with synthetic cannabinoids are unknown, and it remains to be established whether the “contamination” was deliberate or accidental. However, the consequences for people who ingested the mixture were often serious, and sometimes fatal, but this seems unlikely to be due to BFC action at cannabinoid receptors.